Synthesis of Benzophenone Hydrazone Analogs and their DPPH Radical Scavenging and Urease Inhibitory Activities

¹Khalid Mohammed Khan*, ^{1,4}Fazal Rahim, ¹Ajmal Khan, ¹Sajjad Ali, ^{1,5,6}Muhammad Taha, ¹Syed Muhammad Saad, ¹Momin Khan, ²Najeebullah, ²A. Shaikh, ³Shahnaz Perveen and ¹Muhammad. Iqbal Choudhary

¹H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences,

University of Karachi, Karachi-75270, Pakistan.

²Department of Chemistry Federal Urdu University, Gulshan-e-Iqbal, Karachi, Pakistan.

³PCSIR Laboratories Complex, Karachi, Shahrah-e-Dr. Salimuzzaman Siddiqui, Karachi-75280, Pakistan.

⁴Department of Chemistry, Hazara University, Mansehra, Khyber Pukhtoonkhwa, Pakistan.

⁵Atta-ur-Rahman Institute for Natural Product Discovery, UiTM Kampus Puncak Alam,

42300 Bandar Puncak Alam, Selangor, Malaysia.

⁶Faculty of Applied Science, UiTM, 40450 Shah Alam, Selangor Malaysia.

(Received on 6th May 2014, accepted in revised form 3rd December 2014)

Summary: Benzophenone hydrazone analogs **1-25** were synthesized and evaluated for antioxidant (DPPH radical scavenging), and urease inhibitory activities. Out of twenty-five analogs, compounds **8**, **23**, and **1** showed potent free radical scavenging activities with IC₅₀ values 19.45 ± 1.25 , 21.72 ± 1.49 , and $26.0 \pm 0.52 \mu$ M, respectively, while compound **8** (IC₅₀ = $36.36 \pm 0.94 \mu$ M), and **15** (IC₅₀ = $55.5 \pm 0.69 \mu$ M), showed good to moderate urease inhibitory potential.

Keywords: Benzophenone hydrazone, Antioxidant, Urease inhibition.

Introduction

Benzophenones (also called diphenyl ketones) are a class of compounds having a range of biological and chemical significances. Benzophenones display substantial antitumor activity both in vivo and in vitro [1]. Synthetic benzophenones, for instance, dihydroxy-4-methoxy benzophenone [2], and 2-aminobenzophenone [3] have turned out to be anticancer and antimitotic agents, respectively. Benzophenones bearing an amino or a methoxy substituents are found to be potent cytotoxic agents against a panel of multi-drug-resistant cell lines [4]. Some derivatives of benzophenones showed a selective toxicity for the proliferation of endothelial cells by apoptosis induction [16]. Polyprenylated benzophenones were found to have the ability to cause induction of caspasemediated apoptosis [5]. Few years ago, benzophenones with para-methoxy substitutions were assessed as $p38\alpha$ inhibitors and were found to have high selectivity and efficacy [6].

Benzophenone hydrazone analogs are important scaffolds for a variety of biological activities. A nitro-substituted analog has completed a phase-I clinical trials, and objective responses were seen in advanced breast cancer, non-Hodgkin's lymphoma, and melanoma [7]. An important requirement of an iron-chelating drug, such as an antimalarial is a high attraction for iron. Arylhydrazones are biologically important Fe chelators and have been found to possess excellent antimalarial activity [8]. The affinity constant of Some hydrazone derivatives are proteinase inhibitors with antiparasitic activity against *Trypanosoma brucei* [10].

Due to the biological importance of hydrazone molecules, here we are reporting the potential activity of benzophenone hydrazones against urease, and reactive oxygen species (ROS). Ureases are good target for the gastric and peptic ulcers [11]. Reactive oxygen species (ROS) damage the DNA of most of biological systems, which lead to carcinogenesis, heart disease, and many other health problems related to advancing age [12]. Synthetic antioxidants are used by many industries at low concentrations for suppression of radical generation for the prevention of premature polymerization during the course of processing, storage and transportation of the unsaturated monomers etc. Antioxidants scavenge or prevent the generation of ROS [13], thus preventing free radicals formation that would otherwise lead to cancer, cardiovascular diseases, inflammation and neurodegenerative problems [14].

Experimental

Urease Inhibition Assay

Reaction mixtures having 1 unit of urease solution and 55 μ L of buffer containing 100 mM urea were subjected to incubation with 5 μ L of test compounds (1 mM concentration) at 30 °C in 96-well measuring the generation of ammonia evolution by applying the indophenol method. Phenol reagent (45 μ L) and alkali reagent (70 μ L) were added to each well. The increasing absorbance was measured after 50 min at 630 nm, with the help of a microplate reader (Molecular Device, USA). All reactions were carried out in triplicate. The results (change in absorbance per min) were processed with the help of Soft-Max Pro software (Molecular Device, USA) [15].

Determination of % Inhibition

% Inhibition=100-(OD test well / OD control) ×100

Antioxidant assay (DPPH Scavenging assay)

Modified 1,1-diphenyl-2-picrylhydrazyl (DPPH) methods [16, 17] were used for the measurement of potential of free radical scavenging of the compounds. Test compounds were countenanced to react with the stable free radical, 1,1-diphenyl-2picrylhydrazyl radical (DPPH) for the span of 30 min at temperature 37 °C. The molarity of DPPH was held as 300 mM. The test samples were dissolved in DMSO while DPPH was ethanol. After the incubation, decline in absorption was determined at 515 nm with the help of multiplate reader (Spectra MAX-384). Percentage (%) radical scavenging activity (RSA) of the samples was measured by comparison with control, however, DMSO was kept as a positive control [16] using the following formula. All analyses were done three times.

% RSA = 100 - {(OD test compound/OD control) x 100}

Determination of IC₅₀ Values

The concentrations of samples, those which were inhibited the hydrolysis of substrates by 50% (IC₅₀), were determined by monitoring the effect of increasing concentrations of these compounds in the assays on the inhibition values. The IC₅₀ values were then calculated with the help of EZ-Fit Enzyme Kinetics Program (Perrella Scientific Inc., Amherst, U.S.A.).

Results and Discussion

Chemistry

Benzophenone hydrazone derivatives **1-25** were synthesized by reacting commercially available benzophenone hydrazone with various aromatic aldehydes and ketones in anhydrous ethanol [18].

In a typical reaction, few drops of acetic acid were added to a stirred mixture of benzophenone hydrazone (3.0 mmol) and a substituted aromatic aldehyde or ketone (3.0 mmol) in anhydrous ethanol (10 ml), and heated at refluxed for 2-3 h. The reaction progress was monitored by TLC. When the reaction was complete, mixture was allowed to cool at room temperature and precipitates of benzophenone hydrazone derivatives were collected. The precipitates were washed with hexane and dried to afford compounds **1-25** in high yields. Recrystallization from methanol afforded pure crystals of synthetic compounds **1-25** (Scheme 1, Table-1).

Bioactivities

All the synthetic derivatives **1-25** were submitted to *in vitro* DPPH radical scavenging activity as per literature protocol [19, 20]. The derivatives showed reasonable free radical scavenging activities. Out of twenty-five derivatives, three compounds, **8**, **23**, and **1** displayed potent free radical scavenging activities bearing IC₅₀ values 19.45 \pm 1.25, 21.72 \pm 1.49, and 26.0 \pm 0.52 μ M, respectively, upon comparison with the standard, *n*-propyl gallate (IC₅₀ = 30.27 \pm 1.6 μ M) as depicted in Table-2.

All the compounds 1-25 were also randomly screened for their urease inhibitory activities. Compounds 7 (IC₅₀ = 65.77 \pm 0.89 μ M), 6 (IC₅₀ = 98.21 ± 1.67 μ M), **13** (IC₅₀ = 101.08 ± 1.07 μ M), **21** $(IC_{50} = 122.45 \pm 3.17 \ \mu M), 25 \ (IC_{50} = 154.13 \pm 3.52)$ μ M), and 2 (IC₅₀ = 286.59 ± 1.56 μ M) were found to be moderately to weakly active. All the compounds 1-25 were also randomly screened for their urease activities. For urease inhibitory inhibition, compounds, 8 (IC₅₀ = $36.36 \pm 0.94 \mu$ M), 15 (IC₅₀ = 55.5 \pm 0.69 μ M), **1** (IC₅₀ = 102.66 \pm 1.5), **6** (IC₅₀ = 128.76 \pm 0.61), 7 (IC₅₀ = 139.5 \pm 1.12), 23 (IC₅₀ = 192.83 \pm 3.65), **13** (IC₅₀ = 202.46 \pm 2.8), **25** (IC₅₀ = 223.12 \pm 3.52), and **21** (IC₅₀ = 425.62 \pm 2.36) were found to be good to weakly active.

 \mathbf{R}^2



Scheme-1: Syntheses of benzophenone hydrazone derivatives 1-25.Table-1: Synthesis of benzophenone hydrazones analogs 1-25.S. No.R¹R²S. No.R¹



DPPH Radical Scavenging Studies

Compounds **8**, **23** and **1** were explored to be the most active antioxidants among the library of synthesized compounds, with IC₅₀ values of 19.45 ± 1.25, 21.72 ± 1.49, and 26.0 ± 0.52 μ M, respectively, in comparison with standard, *n*-propyl gallate (IC₅₀ = 30.27 ± 1.6 μ M). The free radical scavenging potential of a compound depends upon the ability to stabilize the free radicals. All these compounds **8**, **23** and **1** have three hydroxyl groups installed at the ring. The abstraction of hydrogen by DPPH, generates the stable phenoxide radical. Its stability is due to the extended conjugation. Consequently, good free radical scavenging potential is observed.

Compounds 7, 2,5-dihydroxy, 6, 3,4dihydroxy and 23, 2,3-dihydroxy analogs of benzophenone hydrazones also showed good DPPH scavenging effects with IC₅₀ values 65.77 \pm 0.89, 98.21 \pm 1.67, and 122.45 \pm 3.17 μ M, respectively. The difference in activities seems to be due to the orientation of hydroxyl group on the phenyl part.

Compound 13 (IC_{50} = 101.08 \pm 1.07 μ M) was found to be more active than compound 25 (IC_{50} =

 $154.13 \pm 3.52 \ \mu$ M). The difference in activity may be due to difference in R¹ group. However, decline in activity was observed in compound **2** (IC₅₀ = 286.59 ± 1.56 μ M), which might be due to presence of one hydroxyl and one methoxy group.

Urease Inhibition Studies

Benzophenone hydrazone derivatives 1-25 were screened against urease enzyme according to the literature protocol [18]. These residues showed a diversified degree of urease inhibitory potential having IC₅₀ values in the range of 36.36 \pm 0.94 - $425.62 \pm 2.36 \ \mu M$ comparing with the standard (thiourea IC₅₀ = $21 \pm 0.11 \mu$ M) (Table-2). Compounds, 8 (IC₅₀ = 36.36 \pm 0.94 μ M), and 15 (IC₅₀ = 55.5 \pm 0.69 μ M), displayed good urease inhibitory potential, while compounds, 1 (IC₅₀ = 102.66 \pm 1.5 μ M), 6 (IC₅₀ = $128.76 \pm 0.61 \ \mu\text{M}$), 7 (IC₅₀ = $139.5 \pm 1.12 \ \mu\text{M}$), 7 (IC₅₀ = $192.83 \pm 3.65 \ \mu$ M), **13** (IC₅₀ = $202.46 \pm 2.8 \ \mu$ M), and **25** (IC₅₀ = 223.12 \pm 3.52 μ M) showed moderate inhibition potential against urease. However, compound **21** (IC₅₀ = $425.62 \pm 2.36 \mu$ M) exhibited a weak inhibitory potential.

2,4,6-Trihydroxy substituted analog 8 and 2,6-dihydroxy 15 compound showed inhibitory activities among the series with IC₅₀ values 36.36 \pm 0.94, and 55.5 \pm 0.69 μ M, respectively. 2,3,4-Trihydroxy analog 1 was found to be third most active among the series with IC₅₀ value of 102.66 \pm 1.5 μ M. Interestingly, compound **1** having 2.3.4-trihydroxyl group showed a weak activity than compound 8 (2,4,6trihydroxy analog). The difference in activity between compound 8 and 1 may be due to the position of hydroxyl groups suggesting that position of hydroxyl group at phenyl ring also plays an important role in urease inhibitory activity. Similarly, compound 6, 3,4dihydroxy residue and compound 7, 2,5-dihydroxy analog have IC_{50} values 128.76 \pm 0.61 and 139.5 \pm 1.12 μ M, respectively, by comparing with **15** (IC₅₀ = 55.5 \pm 0.69 μ M) analog which is also a dihydroxy analog. Weak inhibitions of these compounds may be because of variation in the position of hydroxyl group. Compounds 13, 2,5-dihydroxy with R^2 , as a methyl group and 25, a 2,5-dihydroxy analog with R^2 , as an ethyl group have IC₅₀ values 202.46 ± 2.8 and 223.12 \pm 3.52 μ M, respectively. Variation in R² group may be the reason in slight difference in IC₅₀ values.

Among the trihydroxy analogs, compound **23**, 2,4,5-trihydroxy (IC₅₀ = 192.83 \pm 3.65 μ M), exhibited weak inhibition. The reason may be the change in the position of hydroxyl group. Among the dihydroxy analogs, compound **21**, 2,3-dihydroxy has an IC₅₀ value of 425.62 \pm 2.36 μ M, showed weak

inhibition against urease, not only among the dihydroxy analog but also in whole series. The reason seems to be due to the variation in the position of hydroxyl group on benzene ring. All the remaining compounds showed less than 50% inhibition and hence are considered to be inactive.

Table-2: Activities results of benzophenone hydrazone analogs 1-25.

Compound	Urease Inhibition	Antioxidant
No.	$IC_{50} \pm SEM^{a} [\mu M]$	$IC_{50} \pm SEM^{a} [\mu M]$
1	102.66 ± 1.5	26.0 ± 0.52
2	NA ^b	286.59 ± 1.56
3	NA ^b	NA^{b}
4	NA ^b	NA^{b}
5	NA ^b	NA^{b}
6	128.76 ± 0.61	98.21 ± 1.67
7	139.5 ± 1.12	65.77 ± 0.89
8	36.36 ± 0.94	19.45 ± 1.25
9	NA ^b	NA^{b}
10	NA ^b	NA^{b}
11	NA ^b	NA ^b
12	NA ^b	NA^{b}
13	202.46 ± 2.8	101.08 ± 1.07
14	NA ^b	NA^{b}
15	55.5 ± 0.69	NA ^b
16	NA ^b	NA^{b}
17	NA ^b	NA ^b
18	NA ^b	NA^{b}
19	NA ^b	NA ^b
20	NA ^b	NA ^b
21	425.62 ± 2.36	122.45 ± 3.17
22	NA ^b	NA^{b}
23	192.83 ± 3.65	21.72 ± 1.49
24	NA ^b	NA ^b
25	223.12 ± 3.52	154.13 ± 3.52
Standard	Thiourea ^c = 21 ±.0.11	<i>n</i> -Propyl gallate ^c = 30. 27 \pm 1.6

SEM^a is the standard error of the mean, NA^b Not active, Thiourea^c standard inhibitor for anti-urease activity, *n*-propyl gallate^c standard for DPPH radical scavenging assay.

Conclusion

Out of twenty-five benzophenone hydrazone screened analogs, compounds **8** (IC₅₀ = 19.45 ± 1.25), **23** (IC₅₀ = 21.72 ± 1.49) and **1** (IC₅₀ = 26.0 ± 0.52 μ M) showed good radical scavenging activities. However, compound **8** (IC₅₀ = 36.36 ± 0.94 μ M), and **15** (IC₅₀ = 55.5 ± 0.69 μ M), showed good to moderate urease inhibitory potential. Compounds **1**, **8**, **15**, and **23** may serve as lead compounds.

Acknowledgements:

The authors are also thankful to the Higher Education Commission (HEC), Pakistan, for providing financial support for this research work under the National Research Program for Universities (Project No. 20-1910) and Organization for the Prohibition of Chemical Weapons (OPCW), The Netherlands, (Project No. L/ICA/ICB/173681/12).

References

- H. P. Hsieh, J. P. Liou, Y. T. Lin, N. Mahindroo, J. Y. Chang, Y. N. Yang, S. S. Chern, U. K. Tan, C. W. Chang, T. W. Chen, C. H. Lin, Y. Y. Chang and C. C. Wang, *Bioorg. Med. Chem. Lett.*, 13, 101 (2003).
- 2. Y. Nakagawa and T. Suzuki, *Chem. Biol. Interact.*, **139**, 115 (2002).
- J. P. Liuo, C. W. Chang, J. S. Song, Y. N. Yang, C. F. Yeh, H. Y. Tseng, Y. K. Lo, Y. L. Chang, C. M. Chang and H. P. Haiesh, *J. Med. Chem.*, 45, 2556 (2001).
- M. Schlitzer, M. Bohm and I. Sattler, *Bioorg. Med. Chem.*, **10** 615 (2002).
- K. Balasubramanyam, M. Altaf, A. V. Radhika, V. Swaminathan, R. Aarthi, P. Parag and T. P. Sadhal Kundu, *J. Bio. Chem.*, **279**, 33716 (2004).
- L. Revesz, E. Blum, F. E. Di Padova, T. Buhl, R. Feifel, H. Gram, P. Hiestand, U. Manning and G. Rucklin, *Bioorg. Med. Chem. Lett.*, 14, 3601 (2004).
- D. Eilender, P. LoRosso, L. Thomas, C. McCormick, A. H. Rodgers, C. L. Hooper, K. Tornyos, E. T. Krementz, S. Parker and L. R. Morgan, *Cancer Chemother. Pharmacol.*, 57, 719 (2006).
- A. Tsafack, M. Loyevsky, P. Ponka and Z. I. Cabantchik, *J Lab. Clin. Med.*, **127**, 574 (1996).
- P. Ponka, D. R. Richardson, J. T. Edward and F. L. Chubb, *Canadian J. Physiol. Pharmacol.* 72, 659 (1994).
- C. R. Caffrey, M. Schanz, J. Nkemgu-Njinkeng, M. Brush, E. Hansell, F. E. Cohen, T. M. Flaherty,

J. H. McKerrow and D. Steverding, *Int. J. Antimicrob. Ag.*, **19**, 227 (2002).

- M. Arfan, M. Ali, H. Ahmad. I. Anis, A. Khan, M. I. Choudhary and M. R. Shah, *J. Enzyme. Inhib. Med. Chem.* 25, 296 (2010).
- 12. K. Uchida, Free Radical Biol. Med., 28, 1685 (2000).
- 13. J. E. Kinsella, E. Frankel, B. German and J. Kanner, *Food. Technol.*, **47**, 85 (1993).
- 14. R. L. Prior, X. Wu and K. Schaichs, J. Agric. Food. Chem., 53, 4290 (2005).
- Weatherburn, M., Phenol-hypochlorite reaction for determination of ammonia. *Anal. Chem.* 1967, 39, 971-974.
- Y. Fugita, I. Uera, Y. Morimoto, M. Nakajima, C. Hatano and T. Okuda, *Yakugaku Zasshi*, **108**, 129 (1988).
- R. C. Smith, J. C. Reeves, *Biochem. Pharmacol.*, 36, 1457 (1987).
- K. M. Khan, F. Rahim, N. Ambreen, M. Taha, M. Khan, H. Jahan, Najeebullah, A. Shaikh, S. Iqbal, S. Perveen, and M. I. Choudhary, *Med. Chem.*, 9, 588 (2013)
- M. I. Choudhary, A. Begum, A. Abbaskhan, S. G. Musharraf, A. Ejaz and Atta-ur-Rahman, *Chem. Biodiv.*, 5, 2676 (2008).
- I. Khan, S. Ali, S. Hameed, N. H. Rama, M. T. Hussain, A. Wadood, R. Uddin, Zaheer-ul-Haq, A. Khan, S. Ali and M. I. Choudhary, *European J. Med. Chem.*, 45, 5200 (2010).